Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Grote globale verschillen in implementatie van hypofractionering bij radiotherapie
nov 2018 | Borstkanker, Radiotherapie, Uro-oncologie